193 related articles for article (PubMed ID: 29680988)
21. Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice.
Hayashi S; Tsuneto M; Yamada T; Nose M; Yoshino M; Shultz LD; Yamazaki H
Endocrinology; 2004 Jun; 145(6):2721-9. PubMed ID: 14988381
[TBL] [Abstract][Full Text] [Related]
22. miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway.
Zhao C; Sun W; Zhang P; Ling S; Li Y; Zhao D; Peng J; Wang A; Li Q; Song J; Wang C; Xu X; Xu Z; Zhong G; Han B; Chang YZ; Li Y
RNA Biol; 2015; 12(3):343-53. PubMed ID: 25826666
[TBL] [Abstract][Full Text] [Related]
23. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
24. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
25. Osteoblastic NF-κB pathway is involved in 1α, 25(OH)2D3-induced osteoclast-like cells formation in vitro.
Cong L; Zhang C; Tu G
Int J Clin Exp Pathol; 2015; 8(5):5988-96. PubMed ID: 26191332
[TBL] [Abstract][Full Text] [Related]
26. Macrophage lineage phenotypes and osteoclastogenesis--complexity in the control by GM-CSF and TGF-beta.
Lari R; Fleetwood AJ; Kitchener PD; Cook AD; Pavasovic D; Hertzog PJ; Hamilton JA
Bone; 2007 Feb; 40(2):323-36. PubMed ID: 17055352
[TBL] [Abstract][Full Text] [Related]
27. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
28. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
Tsujisawa T; Inoue H; Nishihara T
J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
[TBL] [Abstract][Full Text] [Related]
29. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
30. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
31. Pmepa1 induced by RANKL-p38 MAPK pathway has a novel role in osteoclastogenesis.
Funakubo N; Xu X; Kukita T; Nakamura S; Miyamoto H; Kukita A
J Cell Physiol; 2018 Apr; 233(4):3105-3118. PubMed ID: 28802000
[TBL] [Abstract][Full Text] [Related]
32. Characterization and identification of subpopulations of mononuclear preosteoclasts induced by TNF-α in combination with TGF-β in rats.
Matsubara R; Kukita T; Ichigi Y; Takigawa I; Qu PF; Funakubo N; Miyamoto H; Nonaka K; Kukita A
PLoS One; 2012; 7(10):e47930. PubMed ID: 23110133
[TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
34. Regulation of osteoclastogenesis and RANK expression by TGF-beta1.
Yan T; Riggs BL; Boyle WJ; Khosla S
J Cell Biochem; 2001 Aug 1-9; 83(2):320-5. PubMed ID: 11573248
[TBL] [Abstract][Full Text] [Related]
35. Mitf regulates osteoclastogenesis by modulating NFATc1 activity.
Lu SY; Li M; Lin YL
Exp Cell Res; 2014 Oct; 328(1):32-43. PubMed ID: 25152440
[TBL] [Abstract][Full Text] [Related]
36. The antimicrobial peptide, human β-defensin-1, potentiates in vitro osteoclastogenesis via activation of the p44/42 mitogen-activated protein kinases.
Makeudom A; Supanchart C; Montreekachon P; Khongkhunthian S; Sastraruji T; Krisanaprakornkit J; Krisanaprakornkit S
Peptides; 2017 Sep; 95():33-39. PubMed ID: 28709835
[TBL] [Abstract][Full Text] [Related]
37. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
38. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
39. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
40. Dual effect of WIN-34B on osteogenesis and osteoclastogenesis in cytokine-induced mesenchymal stem cells and bone marrow cells.
Seo BK; Ryu HK; Park YC; Huh JE; Baek YH
J Ethnopharmacol; 2016 Dec; 193():227-236. PubMed ID: 27401292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
